Clinical trials: Disseminated Fungal Infection
- Condition Disseminated Fungal Infection
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Invasive Fungal Infections
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
This study aimed to learn what levels of rezafungin were in the blood after dosing and how safe it was, in children and adolescents below 18 years old who were already receiving treatment for a fungal infection, a suspected…
- Trial name
- NCT05534529
- Testing
- Rezafungin Acetate
- Where
- 10 sites in Germany, Spain and 1 more
- Volunteers
- 32 people
- Sponsor
- Mundipharma Research Limited
Candidiasis, Esophageal, Candidiasis, Invasive
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
- Conditions
- Candidiasis, Esophageal, Candidiasis, Invasive, Aspergillosis
- Trial name
- NCT01165320
- Testing
- Caspofungin
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidemia
A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)
This study will evaluate the incidence rate of Candida blood stream infection (candidemia) among people hospitalized in participating medical centers in Brazil, and will assess the antifungal drug susceptibility patterns of…
- Trial name
- NCT01174147
- Volunteers
- 436 people
- Sponsor
- Merck Sharp & Dohme LLC
Mycobacterium Avium-Intracellulare Infection, HIV Infections
An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy
To evaluate the efficacy and safety of azithromycin given chronically for the treatment of Mycobacterium avium (MAC) bacteremia in patients failing or intolerant of current available MAC therapy.
- Trial name
- NCT00002089
- Testing
- Azithromycin
- Where
- United States
- Sponsor
- Pfizer
Non-tuberculous Mycobacterial Diseases, Tuberculosis
Safety And Efficacy Of Rifabutin In HIV Patients
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Conditions
- Non-tuberculous Mycobacterial Diseases, Tuberculosis, Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
- Trial name
- NCT00810446
- Testing
- rifabutin
- Volunteers
- 72 people
- Sponsor
- Pfizer
Invasive Candidiasis, Candidemia
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
- Trial name
- NCT00189709
- Testing
- Micafungin, fluconazole
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Candidiasis, Systemic, Candida Meningitis
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
The primary purpose of this study is to evaluate the pharmacokinetic profile of micafungin administered to neonates suffering from systemic candidiasis.
- Trial name
- NCT03421002
- Testing
- Micafungin
- Where
- 2 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Candidiasis
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or…
- Trial name
- NCT00106288
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 37 sites in United States, Canada
- Volunteers
- 637 people
- Sponsor
- Astellas Pharma Inc
Bacteremia, Fungemia
Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture
The "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification \& Antimicrobial Susceptibility Testing" is designed to validate the clinical performance of the Accelerate ID/AST…
- Trial name
- NCT02719769
- Where
- 14 sites in United States
- Volunteers
- 4,009 people
- Sponsor
- Accelerate Diagnostics, Inc.
Nosocomial Infections, Sepsis
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing…
- Conditions
- Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
- Trial name
- NCT00113191
- Testing
- Veronate
- Where
- 93 sites in United States, Canada
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Infection, Invasive Fungal
Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)
This retrospective study is designed to provide a consistent method of screening and collecting data on patients who will serve as controls for a comparison of the efficacy of the available antifungal therapies used as salvage…
- Trial name
- NCT00230243
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidemia, Invasive Candidiasis
CRITIC - Treatment of Candidemia and Invasive Candidiasis
Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
- Trial name
- CRITIC (NCT00670657)
- Testing
- AmBisome
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Invasive Fungal Infections
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment…
- Trial name
- NCT06433128
- Testing
- Fosmanogepix solution for infusion, Fosmanogepix 400 mg tablets
- Sponsor
- Basilea Pharmaceutica
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Mycoses, Mycobacterium Avium-Intracellulare Infection
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
PRIMARY: To determine the efficacy of azithromycin and rifabutin alone and in combination for the prevention of disseminated Mycobacterium avium Complex (MAC) infection in HIV-infected patients.
- Conditions
- Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
- Trial name
- NCT00002122
- Testing
- Azithromycin, Rifabutin, Fluconazole
- Where
- 12 sites in United States
- Volunteers
- 720 people
- Sponsor
- Pfizer
Invasive Fungal Infection
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants <2 years of age with invasive fungal infection…
- Trial name
- NCT04665037
- Testing
- Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg
- Where
- 26 sites in United States, Belgium and 8 more
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Mycoses
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A.
- Trial name
- NCT00034632
- Testing
- Posaconazole oral suspension
- Sponsor
- Merck Sharp & Dohme LLC
Mycoses
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A: which are refractory or resistant to…
- Trial name
- NCT00034658
- Testing
- Posaconazole
- Volunteers
- 336 people
- Sponsor
- Merck Sharp & Dohme LLC
Pediatric Safety and Effectiveness
Vfend Special Investigation For Pediatric - Observational
Examine the safety and effectiveness of Vfend [voriconazole] for pediatric under general clinical practices.
- Trial name
- NCT02554656
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Pfizer
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC